Incretin-Based Diabetes Drugs Not Tied to Heart Failure Hospitalizations (FREE)
By Kelly Young
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM
Use of incretin-based drugs for type 2 diabetes — including dipeptidyl-peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 analogues — is not associated with increased risk for …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news
More News: Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Incretin Therapy | Primary Care